Skip to main content

What the FDA labels say about taking them together

Cobicistat and phenobarbital

Cobicistat's FDA label of February 10, 2026 names phenobarbital in its contraindications section; the phenobarbital labels PlainMeds reads (2) do not name cobicistat. The cobicistat label: “Coadministration with carbamazepine, phenobarbital, or phenytoin is contraindicated due to potential for loss of therapeutic effect and development of resistance.”

Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the phenobarbital FDA label on DailyMed (effective August 27, 2026).

What does the cobicistat label say about phenobarbital?

Cobicistat label, contraindications

Alpha 1-adrenoreceptor antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine Antimycobacterial: rifampin Antineoplastics: irinotecan These contraindications apply only to TYBOST coadministered with atazanavir Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products:

Cobicistat label, drug interactions

Concomitant Drug Class/Drug Name: Anticonvulsants: carbamazepine, phenobarbital, phenytoin; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↓ atazanavir ↓ darunavir ↓ cobicistat; Clinical Comment: Coadministration with carbamazepine, phenobarbital, or phenytoin is contraindicated due to potential for loss of therapeutic effect and development of resistance.

Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed

What does the phenobarbital label say about cobicistat?

Phenobarbital's label (effective August 27, 2026) and its 1 other brand-application label do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Phenobarbital), Chartwell RX, LLC, effective August 27, 2026 (SPL set 74428144-fb24-40a5-a670-3b876e2d116c), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Cobicistat generic labelers
0Phenobarbital generic labelers
CobicistatPhenobarbital
Labeled forHIVSeizures and epilepsy
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.213 per tablet 100 mg tablet
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?